Comparative Efficacy and Acceptability of Antidepressants in Parkinson's Disease: A Network Meta-Analysis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Liu, Jinling ^a   Dong, Jiangchuan ^b   Wang, Lei ^c   Su, Ying ^a   Yan, Peng ^a   Sun, Shenggang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATOMOXETINE; DIPYRONE; DOPAMINE RECEPTOR STIMULATING AGENT; NORTRIPTYLINE; PAROXETINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONSTIPATION; DELIRIUM; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EFFECT SIZE; FAINTNESS; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; INTESTINE OBSTRUCTION; LOW DRUG DOSE; META ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIGIDITY; SEXUAL DYSFUNCTION; SHORT QT INTERVAL; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZOTHIAZOLES; DEPRESSION; HUMANS; ODDS RATIO; PARKINSON DISEASE; PERGOLIDE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84884875794     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076651     Document Type: Article

References (51)

1. Shabnam GN, Th C, Kho D, H R, Ce C, (2003) Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 3: CD003465.
2. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, et al. (2005) Antidepressant Studies in Parkinson's Disease: A Review and Meta-Analysis. Mov Disord. 20: 1161-1169.
3. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, et al. (2007) Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol 20: 161-165.
4. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, et al. (2010) Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 10: 49.
5. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, et al. (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72: 886-892.
6. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, et al. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease. Movement Disord 26Suppl 3: S42-80.
7. Caldwell DM, Ades AE, Higgins JP, (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331: 897-900.
8. Thijs V, Lemmens R, Fieuws S, (2008) Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient is chaemic attack or stroke. Eur Heart J 29: 1086-1092.
9. Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME, (2005) Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 17: 310-323.
10. Yang S, Sajatovic M, Walter BL, (2012) Psychosocial interventions for depression and anxiety in Parkinson's disease. J Geriatr Psychiatry Neurol 25: 113-121.
11. Chung TH, Deane KH, Ghazi-Noori S, Rickards H, Clarke CE, (2003) Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord 10: 59-65.
12. Leentjens AF, (2011) The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. Drugs 71: 273-286.
13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
14. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
15. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, et al. (2006) Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 24: 1-19.
16. Salanti G, Higgins JP, Ades AE, Ioannidis JP, (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17: 279-301.
17. Lumley T, (2002) Network meta-analysis for indirect treatment comparisons. Stat Med 21: 2313-2324.
18. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, et al. (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23: 850-857.
19. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, et al. (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson's disease A national multicenter parallel-group randomized study. J Neurol 253: 601-607.
20. Rabey JM, Orlov E, Korczyn AD, (1996) A Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease. Neurology 46: A374.
21. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, et al. (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 573-580.
22. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, et al. (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78: 1229-1236.
23. Antonini A, Tesei S, Zecchinelli A, Barone P, De Gaspari D, et al. (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 21: 1119-1122.
24. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR, (2003) SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 18: 552-554.
25. Wermuth L, Sorensen PS, Timm SE, (1998) Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial. Nord J Psychiatry 52: 163-169.
26. Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, et al. (2003) Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 10: 399-406.
27. Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, et al. (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75: 448-455.
28. Furukawa TA, McGuire H, Barbui C, (2002) Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 325: 991.
29. Moncrieff J, Wessely S, Hardy R (2004) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev: D3012.
30. Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, et al. (2003) Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 23: 509-513.
31. Williams JR, Hirsch ES, Anderson K, Bush AL, Goldstein SR, et al. (2012) A comparison of nine scales to detect depression in Parkinson disease: which scale to use? Neurology 78: 998-1006.
32. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, et al. (2002) Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 10: 125-128.
33. Marsh L, McDonald WM, Cummings J, Ravina B, (2006) Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 21: 148-158.
34. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, et al. (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 573-580.
35. Barone P, (2011) Treatment of depressive symptoms in Parkinson's disease. European Journal of Neurology 18(Suppl. 1): 11-15.
36. Keller MB, (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289: 3152-3160.
37. Senn S, Julious S, (2009) Measurement in clinical trials: a neglected issue for statisticians? Stat Med 28: 3189-3209.
38. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D, (1999) The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 22: 207-212.
39. Goetz CG, Leurgans S, Raman R, (2002) Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 17: 283-288.
40. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, et al. (2010) Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 67: 857-865.
41. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, et al. (2008) Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 23: 690-699.
42. Walsh BT, Seidman SN, Sysko R, Gould M, (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847.
43. Rutherford BR, Mori S, Sneed JR, Pimontel MA, Roose SP, (2012) Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. J Psychiatr Res 46: 697-702.
44. Colloca L, Benedetti F, (2005) Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 6: 545-552.
45. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, et al. (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293: 1164-1166.
46. Goetz CG, Leurgans S, Raman R, (2002) Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 17: 283-288.
47. Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P, (2012) Depression in Parkinson disease--epidemiology, mechanisms and management. Nat Rev Neurol 8: 35-47.
48. Richard IH, Kurlan R, (1997) A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 49: 1168-1170.
49. Okun MS, Fernandez HH, (2009) Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology 72: 868-869.
50. Fernandez HH, Merello M, (2010) Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone? Lancet Neurol 9: 556-557.
51. Kupfer DJ, Frank E, (2002) Placebo in clinical trials for depression: complexity and necessity. JAMA 287: 1853-1854.